Pharmaceutical stocks are getting more attention these days as the global drug market is expected to reach $1.21 trillion in ...

AbbVie Inc. (NYSE: ABBV) delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an ...

Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported ...

If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately.

AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 3.1% on an annualized basis producing an average annual return of 17.03%. Currently, AbbVie has a market capitalization of $383 ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median.

Short Trade IdeaEnter your short position between $211.69 (the intra-day low of its last bearish candlestick) and $217.08 (yesterday's intra-day high).Market Index Analysis <li /> AbbVie ...

In addition to BMO Capital, AbbVie also received a Buy from J.P. Morgan’s Chris Schott in a report issued today. However, on the same day, Bank of America Securities maintained a Hold rating on AbbVie ...

AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised ...

AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ...

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE: ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available options ...